aDivision of Chronic Disease Research Across the Lifecourse (CoRAL), Department of Population Medicine, Harvard Medical School, Harvard Pilgrim Health Care Institute, Boston, MA, USA ...

A glimmer of hope may be on the horizon for a ruthless cancer that former Sen. Ben Sasse (R-Neb.) once called a “definite death sentence.” An experimental treatment from Revolution Medicines helped ...

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

Former Sen. Ben Sasse (R-Neb.) detailed his battle with cancer and reflected on his life during a wide-ranging interview with The New York Times’s Ross Douthat. The conversation, released Thursday as ...